Cargando...

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-oncogene, which confers a more aggressive tumor phenotype and associates with a poor prognosis in patients with this disease. Two approved therapies targeting HER2, the monoclonal antibody trastuzumab and the tyrosine kinas...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rexer, Brent N., Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394454/
https://ncbi.nlm.nih.gov/pubmed/22471661
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!